» Articles » PMID: 30343423

Who Will Win: Induced Pluripotent Stem Cells Versus Embryonic Stem Cells for β Cell Replacement and Diabetes Disease Modeling?

Overview
Journal Curr Diab Rep
Publisher Current Science
Specialty Endocrinology
Date 2018 Oct 22
PMID 30343423
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Ever since the reprogramming of human fibroblasts to induced pluripotent stem cells (hiPSCs), scientists have been trying to determine if hiPSCs can give rise to progeny akin to native terminally differentiated cells as human embryonic stem cells (hESCs) do. Many different somatic cell types have been successfully reprogrammed via a variety of methods. In this review, we will discuss recent studies comparing hiPSCs and hESCs and their ability to differentiate to desired cell types as well as explore diabetes disease models.

Recent Findings: Both somatic cell origin and the reprogramming method are important to the epigenetic state of the hiPSCs; however, genetic background contributes the most to differences seen between hiPSCs and hESCs. Based on our review of the relevant literature, hiPSCs display differences compared to hESCs, including a higher propensity for specification toward particular cell types based on memory retained from the somatic cell of origin. Moreover, hiPSCs provide a unique opportunity for creating diabetes disease models.

Citing Articles

Dual Mode of Mitochondrial ROS Action during Reprogramming to Pluripotency.

Skvortsova E, Nazarov I, Tomilin A, Sinenko S Int J Mol Sci. 2022; 23(18).

PMID: 36142834 PMC: 9506067. DOI: 10.3390/ijms231810924.


Modelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?.

McKnight C, Low Y, Elliott D, Thorburn D, Frazier A Int J Mol Sci. 2021; 22(14).

PMID: 34299348 PMC: 8306397. DOI: 10.3390/ijms22147730.


Modeling Maturity Onset Diabetes of the Young in Pluripotent Stem Cells: Challenges and Achievements.

Braverman-Gross C, Benvenisty N Front Endocrinol (Lausanne). 2021; 12:622940.

PMID: 33692757 PMC: 7937923. DOI: 10.3389/fendo.2021.622940.


Embryonic Stem Cells in Clinical Trials: Current Overview of Developments and Challenges.

Golchin A, Chatziparasidou A, Ranjbarvan P, Niknam Z, Ardeshirylajimi A Adv Exp Med Biol. 2020; 1312:19-37.

PMID: 33159303 DOI: 10.1007/5584_2020_592.


Therapeutic Potential of Wharton's Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges.

Kamal M, Kassem D Front Cell Dev Biol. 2020; 8:16.

PMID: 32064260 PMC: 7000356. DOI: 10.3389/fcell.2020.00016.

References
1.
Jin S, Kim K . Is islet transplantation a realistic approach to curing diabetes?. Korean J Intern Med. 2017; 32(1):62-66. PMC: 5214734. DOI: 10.3904/kjim.2016.224. View

2.
Thurner M, Shenhav L, Wesolowska-Andersen A, Bennett A, Barrett A, Gloyn A . Genes Associated with Pancreas Development and Function Maintain Open Chromatin in iPSCs Generated from Human Pancreatic Beta Cells. Stem Cell Reports. 2017; 9(5):1395-1405. PMC: 5831005. DOI: 10.1016/j.stemcr.2017.09.020. View

3.
Siller R, Naumovska E, Mathapati S, Lycke M, Greenhough S, Sullivan G . Development of a rapid screen for the endodermal differentiation potential of human pluripotent stem cell lines. Sci Rep. 2016; 6:37178. PMC: 5118706. DOI: 10.1038/srep37178. View

4.
Teo A, Windmueller R, Johansson B, Dirice E, Njolstad P, Tjora E . Derivation of human induced pluripotent stem cells from patients with maturity onset diabetes of the young. J Biol Chem. 2013; 288(8):5353-6. PMC: 3581399. DOI: 10.1074/jbc.C112.428979. View

5.
La Spada A, Ntai A, Genovese S, Rondinelli M, De Blasio P, Biunno I . Generation of Human-Induced Pluripotent Stem Cells from Wolfram Syndrome Type 2 Patients Bearing the c.103 + 1G>A CISD2 Mutation for Disease Modeling. Stem Cells Dev. 2017; 27(4):287-295. DOI: 10.1089/scd.2017.0158. View